Journal profile · Infectious Diseases
Microbial Drug Resistance
ISSN 1076-6294 · eISSN 1931-8448 · Mary Ann Liebert Inc. · UNITED STATES · Quarterly · Founded 1995
Microbial Drug Resistance: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 1.79; hybrid open access; review 6–12 weeks (community reports); community-reported acceptance: fairly easy; 54 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Microbial Drug Resistance is published by Mary Ann Liebert Inc. and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Antibiotic Resistance in Bacteria, Antimicrobial Resistance in Staphylococcus and Bacterial biofilms and quorum sensing, together about 39.5% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
Microbial Drug Resistance (MDR) is an international, peer-reviewed journal that covers the global spread and threat of multi-drug resistant clones of major pathogens that are widely documented in hospitals and the scientific community. The Journal addresses the serious challenges of trying to decipher the molecular mechanisms of drug resistance. MDR provides a multidisciplinary forum for peer-reviewed original publications as well as topical reviews and special reports. MDR coverage includes: Molecular biology of resistance mechanisms Virulence genes and disease Molecular epidemiology Drug design Infection control.
Source: LetPub
Research area (LetPub): Infectious Diseases
Editor-in-chief Ivo G. BonecaPublisher website
Editorial board by country: 2 in mainland China (about 5%); most named United States 8, France 7, Germany 4, Brazil 3, Portugal 3 (40 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Antibiotic Resistance in BacteriaBiochemistry, Genetics and Molecular Biology22.9%
- Antimicrobial Resistance in StaphylococcusMedicine9.4%
- Bacterial biofilms and quorum sensingBiochemistry, Genetics and Molecular Biology7.2%
- Pharmaceutical and Antibiotic Environmental ImpactsEnvironmental Science6.2%
- Bacterial Identification and Susceptibility TestingBiochemistry, Genetics and Molecular Biology6%
- Antibiotics Pharmacokinetics and EfficacyMedicine5.5%
- Pneumonia and Respiratory InfectionsMedicine5%
- Salmonella and Campylobacter epidemiologyAgricultural and Biological Sciences3.6%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Infectious Diseases | Zone 4 |
| Minor | Microbiology | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Infectious Diseases | Zone 4 |
| Minor | Microbiology | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Infectious Diseases | Zone 4 |
| Minor | Microbiology | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 1.79LetPub ·
- Impact factor (publisher)
- 1.8Publisher website ·
- 5-year impact factor (publisher)
- 2.1Publisher website ·
- CiteScore 2026-06
- 5LetPub ·
- SJR 2026-06
- 0.61LetPub ·
- SNIP 2026-06
- 0.64LetPub ·
- h-index
- 62LetPub ·
- h-index
- 90OpenAlex ·
- i10-index
- 1,842OpenAlex ·
- 2-year mean citedness
- 1.57OpenAlex ·
- Self-citation rate
- 5.6%LetPub ·
- Share of gold OA articles
- 5.23%LetPub ·
Volume
- Articles per year
- 51LetPub ·
Articles by year OpenAlex count · 2,672 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 69 | 2 | 18 |
| 2025 | 54 | 5 | 94 |
| 2024 | 54 | 4 | 166 |
| 2023 | 81 | 9 | 475 |
| 2022 | 98 | 17 | 923 |
| 2021 | 140 | 18 | 1,638 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
- Average review time (community reports)
- 6–12 weeksLetPub ·
- Average acceptance (community reports)
- Fairly easyLetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
No source has fee information yet; check the journal's website.
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Mary Ann Liebert Inc.
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- Quarterly
- Founded
- 1995
- ISSN
- 1076-6294
- Electronic ISSN
- 1931-8448
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Microbial Drug Resistance
What CAS zone is Microbial Drug Resistance in?
In the 2025 upgraded edition of the CAS Journal Ranking, Microbial Drug Resistance is in Zone 4 of Medicine, and in Zone 4 of the minor category Infectious Diseases / Microbiology / Pharmacology & Pharmacy. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Microbial Drug Resistance?
The latest impact factor listed by LetPub is 1.79; CiteScore 5, h-index 90.
How long does peer review take at Microbial Drug Resistance?
Authors report an average review time of 6–12 weeks; the community-reported acceptance is “Fairly easy”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Microbial Drug Resistance based?
Of the 40 board members whose country the journal's board page names, 2 (about 5%) are in mainland China; the countries named most often are United States (8), France (7) and Germany (4). Counted from the institutions listed on the board page; for reference only.
Which databases index Microbial Drug Resistance?
According to LetPub and DOAJ records, Microbial Drug Resistance is indexed in SCIE and Scopus.
Is Microbial Drug Resistance open access, and what is the APC?
Microbial Drug Resistance is a hybrid journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .